About Matinas BioPharma (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-195.09%
Return on Assets-79.34%
Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions
What is Matinas BioPharma's stock symbol?
Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."
How were Matinas BioPharma's earnings last quarter?
Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.04) EPS for the quarter, topping the Zacks' consensus estimate of ($0.05) by $0.01. The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.05 million. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%. View Matinas BioPharma's Earnings History.
Where is Matinas BioPharma's stock going? Where will Matinas BioPharma's stock price be in 2017?
3 equities research analysts have issued 1 year target prices for Matinas BioPharma's shares. Their forecasts range from $6.00 to $9.00. On average, they anticipate Matinas BioPharma's stock price to reach $7.67 in the next twelve months. View Analyst Ratings for Matinas BioPharma.
What are Wall Street analysts saying about Matinas BioPharma stock?
Here are some recent quotes from research analysts about Matinas BioPharma stock:
- 1. Maxim Group analysts commented, "Summary Matinas stock is down sharply today on news that MAT2203’s efficacy in VVC (vulvovaginal candidiasis) fell well below expectations both internal and external, but wait a second…Was it ever supposed to compare?." (6/26/2017)
- 2. Aegis analysts commented, "Matinas reported the results of the Phase I study testing safety, tolerability and pharmacokinetics of MAT2501, its cochleated version of amikacin. This announcement meets the endpoints and time frame we had expected. Separately, we have received inquiries regarding comments posted to a financial website to which we attribute the recent volatility in the stock. We believe these comments are based on incorrect information, and reiterate our Buy rating on the stock." (3/28/2017)
Are investors shorting Matinas BioPharma?
Matinas BioPharma saw a drop in short interest in November. As of November 30th, there was short interest totalling 1,873,864 shares, a drop of 6.2% from the November 15th total of 1,998,494 shares. Based on an average daily volume of 173,935 shares, the short-interest ratio is presently 10.8 days. Currently, 2.6% of the company's stock are sold short.
Who are some of Matinas BioPharma's key competitors?
Some companies that are related to Matinas BioPharma include GTX (GTXI), Arbutus Biopharma (ABUS), Corvus Pharmaceuticals (CRVS), Nabriva Therapeutics (NBRV), CASI Pharmaceuticals (CASI), Palatin Technologies (PTN), Zynerba Pharmaceuticals (ZYNE), Pluristem Therapeutics (PSTI), Oncomed Pharmaceuticals (OMED), Organovo (ONVO), Silence Therapeutics (SLN), Curis (CRIS), Merrimack Pharmaceuticals (MACK), Advaxis (ADXS), Eiger BioPharmaceuticals (EIGR), Compugen (CGEN), Oramed Pharmaceuticals (ORMP) and ArQule (ARQL).
Who are Matinas BioPharma's key executives?
Matinas BioPharma's management team includes the folowing people:
- Jerome D. Jabbour J.D., President (Age 42)
- Roelof Rongen, Chief Executive Officer, Director (Age 51)
- Gary Gaglione CPA, Vice President of Finance and Accounting and Acting Chief Financial Officer (Age 64)
- Douglas F. Kling, Senior Vice President - Clinical Development (Age 43)
- Abdel A. Fawzy Ph.D., Executive Vice President for Pharmaceutical and Supply Chain Development (Age 66)
- Dominick M. Dipaolo, Senior Vice President - Quality and Regulatory Compliance (Age 41)
- Raphael J. Mannino Ph.D., Chief Scientific Officer (Age 70)
- Herbert J. Conrad, Chairman of the Board (Age 84)
- Eric J. Ende M.D., Director (Age 48)
- Adam K. Stern, Director (Age 53)
Who owns Matinas BioPharma stock?
Matinas BioPharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Yellowstone Partners LLC (0.16%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.
Who bought Matinas BioPharma stock? Who is buying Matinas BioPharma stock?
Matinas BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Yellowstone Partners LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.
How do I buy Matinas BioPharma stock?
Shares of Matinas BioPharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Matinas BioPharma's stock price today?
One share of Matinas BioPharma stock can currently be purchased for approximately $1.49.
How big of a company is Matinas BioPharma?
Matinas BioPharma has a market capitalization of $139.43 million.
How can I contact Matinas BioPharma?
Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.
MarketBeat Community Rating for Matinas BioPharma (MTNB)MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings History and Estimates Chart
Matinas BioPharma (NYSEAMERICAN MTNB) Earnings History by Quarter
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/15/2017||Q3 2017||($0.05)||($0.04)||$0.05 million||$0.05 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.04)||$0.02 million||$0.05 million||View||Listen|
|5/16/2017||Q1 2017||($0.04)||($0.25)||$0.02 million||View||N/A|
|11/10/2015||Q3 2016||($0.03)||($0.11)||$0.10 million||$0.06 million||View||N/A|
|8/13/2015||Q2 2015||($0.05)||($0.04)||$0.10 million||$0.08 million||View||N/A|
Matinas BioPharma (NYSEAMERICAN:MTNB) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Matinas BioPharma (NYSEAMERICAN:MTNB)
No dividend announcements for this company have been tracked by MarketBeat.com
Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines
Matinas BioPharma (NYSEAMERICAN:MTNB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Matinas BioPharma (NYSEAMERICAN MTNB) Stock Chart for Thursday, December, 14, 2017